Brokerages Expect Uniqure NV (QURE) to Announce -$0.63 Earnings Per Share

Analysts expect that Uniqure NV (NASDAQ:QURE) will post ($0.63) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Uniqure’s earnings, with the lowest EPS estimate coming in at ($0.70) and the highest estimate coming in at ($0.55). Uniqure posted earnings of ($0.40) per share during the same quarter last year, which would indicate a negative year over year growth rate of 57.5%. The company is scheduled to announce its next quarterly earnings results on Wednesday, November 7th.

According to Zacks, analysts expect that Uniqure will report full year earnings of ($2.44) per share for the current year, with EPS estimates ranging from ($3.34) to ($1.96). For the next year, analysts anticipate that the company will post earnings of ($2.84) per share, with EPS estimates ranging from ($3.76) to ($2.40). Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that cover Uniqure.

Uniqure (NASDAQ:QURE) last announced its quarterly earnings data on Wednesday, August 8th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.04. Uniqure had a negative return on equity of 72.12% and a negative net margin of 677.98%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $3.37 million.

A number of research analysts have recently issued reports on QURE shares. Janney Montgomery Scott reaffirmed a “buy” rating on shares of Uniqure in a research note on Wednesday, August 8th. Cantor Fitzgerald started coverage on Uniqure in a research note on Thursday, July 26th. They set an “overweight” rating and a $58.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Uniqure in a research note on Monday, August 13th. HC Wainwright set a $42.00 price objective on Uniqure and gave the company a “buy” rating in a research note on Thursday, August 23rd. Finally, BidaskClub cut Uniqure from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, August 1st. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the stock. Uniqure presently has a consensus rating of “Buy” and an average price target of $44.89.

Shares of NASDAQ:QURE opened at $41.25 on Friday. Uniqure has a 12-month low of $7.97 and a 12-month high of $43.23. The stock has a market cap of $1.52 billion, a PE ratio of -14.03 and a beta of 0.24. The company has a current ratio of 8.36, a quick ratio of 8.36 and a debt-to-equity ratio of 0.06.

Several institutional investors have recently bought and sold shares of QURE. OppenheimerFunds Inc. purchased a new stake in shares of Uniqure during the second quarter worth about $63,553,000. Redmile Group LLC purchased a new stake in shares of Uniqure during the second quarter worth about $61,402,000. Federated Investors Inc. PA purchased a new stake in shares of Uniqure during the first quarter worth about $21,573,000. Millennium Management LLC boosted its holdings in shares of Uniqure by 242.8% during the first quarter. Millennium Management LLC now owns 759,585 shares of the biotechnology company’s stock worth $17,850,000 after purchasing an additional 538,031 shares during the period. Finally, FMR LLC boosted its holdings in shares of Uniqure by 16.6% during the second quarter. FMR LLC now owns 3,694,681 shares of the biotechnology company’s stock worth $139,659,000 after purchasing an additional 526,283 shares during the period. Institutional investors own 59.33% of the company’s stock.

About Uniqure

uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. The company develops AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia; and AMT-126, a gene therapy for the treatment of congestive heart failure and AMT-130 to treat huntington's disease.

Featured Story: Outstanding Shares

Get a free copy of the Zacks research report on Uniqure (QURE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Uniqure (NASDAQ:QURE)

Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply